Fusion Antibodies (LON:FAB) Trading 17.2% Higher – Should You Buy?

Fusion Antibodies plc (LON:FAB)’s stock price shot up 17.2% during mid-day trading on Tuesday . The stock traded as high as GBX 8.50 ($0.11) and last traded at GBX 8.50 ($0.11). 1,030,108 shares were traded during mid-day trading, a decline of 39% from the average session volume of 1,693,661 shares. The stock had previously closed at GBX 7.25 ($0.09).

Fusion Antibodies Stock Performance

The company has a 50 day moving average price of GBX 7.77 and a 200-day moving average price of GBX 5.20. The company has a quick ratio of 2.36, a current ratio of 3.87 and a debt-to-equity ratio of 2.40. The company has a market cap of £8.11 million, a P/E ratio of -212.50 and a beta of 0.49.

Fusion Antibodies (LON:FAB) last released its earnings results on Tuesday, November 19th. The company reported GBX (0.80) (($0.01)) EPS for the quarter. Fusion Antibodies had a negative net margin of 195.95% and a negative return on equity of 152.68%. Equities analysts expect that Fusion Antibodies plc will post -129.9999875 EPS for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.